Microvast Holdings announces departure of chief financial officer
Eric Karas, Chief Commercial Officer of ARS Pharmaceuticals, Inc. (NASDAQ:SPRY), a company whose stock has delivered a remarkable 104% return over the past year and currently commands a market capitalization of $1.55 billion, sold 15,000 shares of common stock at $16.0 per share on June 18, 2025, for a total of $240,000.
According to a Form 4 filing with the Securities and Exchange Commission, the sale was executed under a Rule 10b5-1 trading plan adopted on March 26, 2024. Following the transaction, Karas directly owns 7,696 shares of ARS Pharmaceuticals. InvestingPro data shows the company maintains strong financial health with a GREAT overall score, offering investors comprehensive insights through its detailed Pro Research Report.
On the same day, Karas also exercised options to acquire 15,000 shares of common stock at an exercise price of $1.50, for a total value of $22,500. These options were immediately exercisable and part of a stock option grant that expires on May 23, 2032. Following the exercise of the options, Karas directly owns 559,588 options. With analyst price targets ranging from $26 to $40, significantly above the current trading price of $15.80, investors may find value in monitoring this stock’s trajectory.
In other recent news, ARS Pharmaceuticals reported its Q1 2025 earnings, with revenue surpassing forecasts at $8 million, largely due to the successful launch of its needle-free epinephrine treatment, NEFI. Despite this revenue beat, the company experienced a net loss of $33.9 million, or $0.35 per share, which slightly missed the forecasted EPS of -$0.3381. The launch of NEFI, which also received FDA approval for a pediatric dose in March 2025, marks a significant milestone for the company. Additionally, ARS Pharmaceuticals anticipates a sales inflection in Q3 2025, with peak sales expected in August and September. The company is also progressing with regulatory reviews in international markets, including the UK and Japan, with launches expected from mid-2025 to early 2026. Furthermore, ARS Pharmaceuticals has launched a direct-to-consumer campaign titled "Hello NEFI, Goodbye Needles" to increase product awareness and adoption. The company is working to expand its market access, with 57% of U.S. commercial lives currently having access to NEFI without prior authorization.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.